Learning from HIV: how will drug resistance influence treatment strategies against hepatitis C?
Durantel
David
D
Molecular Physiopathology and New Treatments for Hepatitis Viruses, INSERM, U871, Lyon, France. durantel@lyon.inserm.fr
Zoulim
Fabien
F
D015195:Drug Design; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans